Effect of mirtazapine in depressive functional dyspepsia patients with weight loss

Abstract

Objective To discuss the effect of mirtazapine in depressive functional dyspepsia patients with weight loss (FD-WL). Methods As a randomized and controlled trial, seventy-two FD patients with weight loss and depression were randomly divided into mirtazapine group(n=24), paroxetine group(n=23) and conventional group(n=25), and all patients were treated for 8 weeks. The Nepean Dyspepsia Index (NDI)- symptom checklist, the Hamilton Rating Scale of Depression (HAMD), body weight were assessed before the treatment and after 2, 4, 6, 8 week. Results (1) After 2-week treatment, the scores of NDI-symptom checklist and HAMD in mirtazapine group were significantly lower than that in paroxetine group and conventional group. After 4-week, 6-week and 8-week treatment, the score of HAMD in mirtazapine group((13.34±1.52), (11.65±1.56), (10.15±1.36)) and paroxetine group((13.65±1.81), (11.34±1.21), (9.58±1.41))was significantly lower than that in conventional group((18.15±1.61), (17.20±2.14), (15.30±1.56)) (all P 0.05). (2) After 6-week and 8-week treatment, the body weight in mirtazapine group((53.17±6.46)kg, (53.55±6.52)kg)was significantly higher compared with that in paroxetine group((49.47±5.72)kg, (49.57±5.81)kg)and conventional group((48.69±5.60)kg, (48.68±5.65)kg)(all P<0.05). After 8-week treatment, patients in mirtazapine group experienced a weight gain of(3.34±1.82)kg. Conclusion Mirtazapine not only can significantly improve dyspepsia symptoms and depressive scoring, but also can increase body weight. Key words: Functional dyspepsia; Weight loss; Mirtazapine; Depression